Abemaciclib, an orally bioavailable and highly selective competitive inhibitor of CDK4/6, has been approved for treating refractory hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic BC [19]. This evidence concerns the gene CDK4 and breast cancer.